Oak Ridge Investments LLC Lowers Stock Holdings in argenx SE (NASDAQ:ARGX)

Oak Ridge Investments LLC lowered its stake in argenx SE (NASDAQ:ARGX) by 60.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,769 shares of the company’s stock after selling 2,696 shares during the period. Oak Ridge Investments LLC’s holdings in argenx were worth $1,088,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ARGX. Cromwell Holdings LLC grew its stake in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the last quarter. GAMMA Investing LLC boosted its stake in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in argenx during the 2nd quarter valued at about $76,000. Fulton Bank N.A. bought a new stake in argenx during the 4th quarter valued at about $226,000. Finally, Blue Trust Inc. raised its holdings in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock worth $201,000 after buying an additional 298 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ARGX shares. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “hold” rating to a “sell” rating in a research note on Friday. Oppenheimer restated an “outperform” rating and issued a $675.00 price target (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. Guggenheim increased their price objective on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Wedbush reissued an “outperform” rating and issued a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Trading Down 2.9 %

argenx stock opened at $640.52 on Friday. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21. The firm has a market capitalization of $38.67 billion, a price-to-earnings ratio of -727.86 and a beta of 0.59. The firm has a 50 day moving average of $620.19 and a 200 day moving average of $556.51.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. The firm had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period last year, the firm earned ($1.25) EPS. On average, analysts predict that argenx SE will post 2.17 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.